

# Provider Update

## NEWS FOR THE NETWORK

April 2023

*Provider Update* is a monthly, online provider newsletter. We encourage you to [register](#) to receive *Provider Update* by email. If you have registered for email distribution but aren't receiving *Provider Update* at the beginning of each month, look in your spam folder or check with your organization's system administrator to ensure the organization's firewall is adjusted to allow for receipt of *Provider Update* from (SENDER: [providerupdate@email-carepartnersct.com](mailto:providerupdate@email-carepartnersct.com)).

## Reminders and Updates

### Prior authorization for new-to-market medical drugs

CarePartners of Connecticut now requires prior authorization for coverage of the following medications:

- **Stimufend** (HCPSC Q5127) (a biosimilar of Neulasta) and Rolvedon (HCPSC J1449) were both approved by the FDA in September 2022 to treat patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
- **Spevigo** (HCPSC J1747) is a novel selective monoclonal antibody approved by the FDA in September 2022 for the treatment of generalized pustular psoriasis.
- **Tecvayli** (HCPSC C9148) was approved by the FDA in October 2022 for relapsed or refractory multiple myeloma.
- **Lunsumio** (HCPSC J9999) was approved by the FDA in December 2022 to treat adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
- **Tzeild** (HCPSC C9149) was approved by the FDA in November 2022 to delay the onset of Stage 3 type 1 diabetes in adults and pediatric patients 8 years of age and older with Stage 2 type 1 diabetes.
- **Skyrizi** (HCPSC J2327) was approved by the FDA in January 2023 to treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, active psoriatic arthritis, and moderately to severely active Crohn's disease.
- **Hemgenix** (J1411) is an adeno-associated virus vector-based gene therapy approved by the FDA in November 2022 for the treatment of adults with Hemophilia B.

For more information, please refer to the following medical necessity guidelines, which outline the clinical coverage criteria that must be met for prior authorization of these drugs, approved indications, coverage limitations, and more.

- [Neutropenia Colony Stimulating Agents – Long Acting Medical Necessity Guidelines](#)
- [Medicare Part B Step Therapy Medical Necessity Guidelines](#)
- [Spevigo Medical Necessity Guidelines](#)
- [Tecvayli Medical Necessity Guidelines](#)
- [Lunsumio Medical Necessity Guidelines](#)
- [Tzeild Medical Necessity Guidelines](#)

- [Skyrizi Medical Necessity Guidelines](#)
- [Hemgenix Medical Necessity Guidelines](#)

In addition, we've updated the criteria on the [Continuous Glucose Monitoring Systems: Freestyle Libre 2 and Dexcom G6 Medical Necessity Guidelines](#) to align with CMS's Glucose Monitors Local Coverage Determination (L33822). This LCD previously required three or more daily administrations of insulin and that the member be treated with a continuous subcutaneous insulin pump, but now requires that the member be insulin treated and have a history of problematic hypoglycemia in order to be covered.

We've also updated our [Xolair Medical Necessity Guidelines](#) to:

- Distinguish medical benefit dosage from pharmacy benefit dosage
- Clarify that Xolair 75mg and 150mg prefilled syringes are covered under the member's prescription drug benefit if Xolair is being self-administered. ♦

## Home infusion claims update

[As previously communicated](#) and effective for dates of service beginning April 1, 2023, CarePartners of Connecticut is insourcing claims pricing and processing for home infusion services. CarePartners of Connecticut will apply edits in our processing systems in accordance with our policies and procedures, and industry standard edits. Currently, home infusion claims for the products noted above are submitted to CVS Health-Novologix.

- For home infusion services **with dates of service prior to April 1, 2023**: Providers may continue to submit these claims to Novologix until June 30, 2023. You will have viewing access with Novologix to check the status of claims through July 1, 2023.
- For home infusion services **with dates of service of April 1, 2023 and beyond**: Providers should submit these claims to CarePartners of Connecticut and should bill using industry standard HCPCS codes to ensure claims are processed accurately.

Claims filing limits still apply. Claims for professional or outpatient services must be received by CarePartners of Connecticut within 60 days of the date of service, or within 60 days of the date of hospital discharge for inpatient or institutional services. For the fastest processing, we encourage electronic claims submission; alternatively, you can mail claims directly to CarePartners of Connecticut at: **CarePartners of Connecticut, P.O. Box 518, Canton, MA 02021** ♦

## Register for upcoming provider training

We offer trainings regularly to update providers and office staff on our CarePartners of Connecticut product. Please join us on [Wednesday, April 19 from 10-11 a.m.](#) for an interactive Overview and Updates session. ♦

## Helpful reminders for providers

- **Avoid Printing:** All CarePartners of Connecticut provider documentation is updated regularly. For the most current information, providers should view all documentation online at [carepartnersct.com/for-providers](https://carepartnersct.com/for-providers) and avoid printing.
- **Browser Note:** If you are using an outdated or unsupported browser, certain features on CarePartners of Connecticut's website may be unavailable. For an improved user experience, upgrade your browser to the latest version of Mozilla Firefox or Google Chrome.
- **Secure Provider Portal Self-Service Tools:** CarePartners of Connecticut's online self-service tools enable providers to electronically submit transactions and/or access information related to claims submission, claims status, referrals, prior authorizations, electronic remittance advice, member eligibility, panel information and more. Log in to the secure Provider portal to manage transactions online. ♦

**Not yet registered?**

Information on how to [register for secure access](#) is available on CarePartners of Connecticut's public Provider [website](#).

**For more information:** [Public Provider Website](#); [Secure Provider Portal](#)

**Contact information:** Call Provider Services at 888-341-1508, weekdays, 8 a.m.-5 p.m.